Balingit, Lovelyn Rose .
HRN: 25-17-01 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/31/2024
CEFUROXIME 500MG (TAB)
05/31/2024
06/06/2024
PO
500mg
Bid
Post Cs
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueIntra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes